Shares of Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) traded up 4.4% during mid-day trading on Friday. The stock traded as high as $46.57 and last traded at $46.5990. Approximately 741,909 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 1,611,652 shares. The stock had previously closed at $44.63.
Heartflow News Summary
These are some of the HTFL news items that stood out recently:
- Positive Sentiment: A recent report says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially supporting the stock’s recent strength. The article excerpt provided does not include the revenue figures or revised guidance details. Article: HeartFlow (HTFL) Surges as Q2 Revenue Beats Consensus and Full-Year Guidance Is Raised
- Negative Sentiment: Put-option trading jumped to 6,628 contracts, about 558% above the reported average volume. This indicates increased demand for downside protection or bearish bets, though options activity alone does not establish traders’ outlook. Heartflow stock information
- Negative Sentiment: Insider Campbell Rogers has reported multiple share sales, including a recent sale of 16,918 shares. Repeated selling can weigh on sentiment, although the reported transactions were made under a pre-arranged Rule 10b5-1 plan. Article: Heartflow Insider Sells 16,918 Shares
Analyst Upgrades and Downgrades
A number of research firms have recently commented on HTFL. Wall Street Zen upgraded shares of Heartflow from a "hold" rating to a "buy" rating in a research note on Sunday, November 15th. Wells Fargo & Company lifted their target price on Heartflow from $39.00 to $70.00 and gave the company an "overweight" rating in a research report on Friday, November 13th. JPMorgan Chase & Co. upped their target price on Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a report on Friday, August 14th. Stifel Nicolaus increased their price target on Heartflow from $45.00 to $70.00 and gave the company a "buy" rating in a research report on Friday, November 13th. Finally, Morgan Stanley raised their price target on Heartflow from $35.00 to $40.00 and gave the company an "equal weight" rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $60.12.
Read Our Latest Analysis on Heartflow
Heartflow Stock Up 4.3%
The business's 50 day simple moving average is $51.82 and its 200 day simple moving average is $35.55. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -50.44 and a beta of 2.50.
Heartflow (NASDAQ:HTFL - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative net margin of 33.11% and a negative return on equity of 20.53%. The company had revenue of $72.86 million for the quarter. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. Equities research analysts forecast that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Vikram Verghese sold 29,714 shares of the business's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $50.06, for a total transaction of $1,487,482.84. Following the transaction, the chief financial officer directly owned 184,789 shares of the company's stock, valued at approximately $9,250,537.34. The trade was a 13.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 24,188 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $46.39, for a total value of $1,122,081.32. Following the completion of the sale, the insider owned 64,424 shares in the company, valued at approximately $2,988,629.36. This trade represents a 27.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,936 shares of company stock valued at $16,355,191 over the last 90 days. 7.70% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Heartflow
Several large investors have recently modified their holdings of the stock. XXEC Inc. bought a new stake in shares of Heartflow during the 2nd quarter worth about $2,524,764,000. BlackRock Inc. bought a new position in Heartflow in the 2nd quarter valued at about $152,502,000. Bamco Inc. NY bought a new position in Heartflow in the 2nd quarter valued at about $94,625,000. Jupiter Topco LLC acquired a new stake in Heartflow during the second quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC lifted its position in Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company's stock worth $53,063,000 after acquiring an additional 1,315,416 shares during the last quarter.
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient's coronary arteries and provide information that can support diagnosis and treatment planning. The company's offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Heartflow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list.
While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.